Biogen Inc. (ETR:IDP)
103.85
-1.65 (-1.56%)
Apr 25, 2025, 5:35 PM CET
Biogen Revenue
In the year 2024, Biogen had annual revenue of $9.68B USD, down -1.62%. Biogen had revenue of $2.45B in the quarter ending December 31, 2024, with 2.87% growth.
Revenue
$9.68B
Revenue Growth
-1.62%
P/S Ratio
1.64
Revenue / Employee
$1.27M
Employees
7,605
Market Cap
15.31B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Merck KGaA | 21.16B |
Siemens Healthineers AG | 22.67B |
Fresenius SE & Co. KGaA | 21.83B |
Bayer Aktiengesellschaft | 46.61B |
Sartorius Aktiengesellschaft | 3.44B |
Fresenius Medical Care AG | 19.34B |
Carl Zeiss Meditec AG | 2.08B |
Fielmann Group AG | 2.16B |
Biogen News
- 1 day ago - Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent? - Seeking Alpha
- 10 days ago - Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion - Benzinga
- 11 days ago - Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union - GlobeNewsWire
- 11 days ago - Biogen/ Eisai win EU approval for Alzheimer’s therapy - Seeking Alpha
- 11 days ago - EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease - Reuters
- 17 days ago - Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag - Seeking Alpha
- 22 days ago - Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks - Benzinga
- 22 days ago - Biogen downgraded to Hold at Argus on profit decline expectations - Seeking Alpha